Despite many recent advances in prevention and treatment interventions for HIV and substance use, policymakers and providers have been forced to confront a persistent insufficiency of funds and to make difficult choices from among competing claims on scarce resources. In this renewal application, we propose to continue our work to address emerging questions about global HIV prevention, treatment, and priority setting in substance-using populations. We will extend our prior epidemiologic modeling work by assessing portfolios of prevention and treatment interventions, by addressing these interventions in the context of co-epidemics (HIV, hepatitis C virus infection, and tuberculosis), and by developing resource allocation tools. The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of alternative portfolio investments.
Our aims are: 1. To estimate production functions that characterize the relationship between program expenditures and health-related outcomes, such as reductions in transmission risk for prevention programs and the delivery of services for treatment programs. 2. To develop model-based methods to translate the behavioral and biological impact of HIV-related interventions into epidemic outcomes, such as infections averted and years of life saved. 3. To determine how best to estimate health outcomes, costs, and cost-effectiveness of HIV and substance use interventions (for example, in the presence of co-epidemics). 4. To assess the individual- and population-level effectiveness, cost, cost-effectiveness, and budget impact of specific interventions aimed at preventing and treating HIV and substance use and related co-epidemics (e.g., HIV, HCV, and tuberculosis). 5. To inform the allocation of societal resources by examining the effectiveness and cost- effectiveness of portfolios of prevention and treatment interventions in the context of the regional epidemiology of disease. 6. To develop practical resource allocation tools for policymakers to assist them in making informed investments of resources in HIV and substance use treatment and prevention programs. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment. The proposed work will enable us to have broad impact on HIV and substance use policy in the U.S. and internationally.

Public Health Relevance

The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of interventions for HIV and substance use. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01DA015612-12
Application #
8651905
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Hartsock, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Stanford
State
CA
Country
United States
Zip Code
94304
Gilbert, Jennifer A; Shenoi, Sheela V; Moll, Anthony P et al. (2016) Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 11:e0165614
Bendavid, Eran (2016) Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health. Curr HIV/AIDS Rep 13:256-62
Brandeau, Margaret L (2016) Creating impact with operations research in health: making room for practice in academia. Health Care Manag Sci 19:305-312
Bendavid, Eran; Stauffer, David; Remera, Eric et al. (2016) Mortality along the continuum of HIV care in Rwanda: a model-based analysis. BMC Infect Dis 16:728
Bilinski, Alyssa M; Fitzpatrick, Meagan C; Rupprecht, Charles E et al. (2016) Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proc Biol Sci 283:
Fu, Rui; Gutfraind, Alexander; Brandeau, Margaret L (2016) Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 273:102-13
Yan, Isabel; Bendavid, Eran; Korenromp, Eline L (2016) Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis. PLoS One 11:e0160481
Glaubius, Robert L; Parikh, Urvi M; Hood, Greg et al. (2016) Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. Open Forum Infect Dis 3:ofw125
Chang, Wei; Chamie, Gabriel; Mwai, Daniel et al. (2016) Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr 73:e39-e45
Juusola, Jessie L; Brandeau, Margaret L (2016) HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment. Med Decis Making 36:391-409

Showing the most recent 10 out of 129 publications